US approves updated Pfizer, Moderna shots targeting Omicron / Photo: © AFP/File
RBGPF
1.2400
The China Mail - US approves updated Pfizer, Moderna shots targeting Omicron
USD
-
AED 3.67302
AFN 68.328423
ALL 83.506912
AMD 383.77791
ANG 1.789699
AOA 917.000202
ARS 1325.573201
AUD 1.536629
AWG 1.8025
AZN 1.705683
BAM 1.679887
BBD 2.019988
BDT 121.546582
BGN 1.6797
BHD 0.377
BIF 2983.211864
BMD 1
BND 1.285415
BOB 6.937722
BRL 5.446401
BSD 1.000404
BTN 87.682152
BWP 13.460572
BYN 3.294495
BYR 19600
BZD 2.009594
CAD 1.378475
CDF 2889.999737
CHF 0.811265
CLF 0.024713
CLP 969.479833
CNY 7.181503
CNH 7.192795
COP 4050.91
CRC 505.91378
CUC 1
CUP 26.5
CVE 94.712294
CZK 21.062982
DJF 178.154379
DKK 6.42083
DOP 61.105552
DZD 129.970435
EGP 48.49103
ERN 15
ETB 139.476128
EUR 0.86032
FJD 2.256397
FKP 0.743585
GBP 0.744685
GEL 2.69594
GGP 0.743585
GHS 10.554751
GIP 0.743585
GMD 72.511502
GNF 8675.14999
GTQ 7.675558
GYD 209.256881
HKD 7.84998
HNL 26.240181
HRK 6.479901
HTG 131.005042
HUF 340.459949
IDR 16309.5
ILS 3.41767
IMP 0.743585
INR 87.731303
IQD 1310.582667
IRR 42124.99974
ISK 123.030239
JEP 0.743585
JMD 160.172472
JOD 0.708984
JPY 147.869498
KES 129.199154
KGS 87.428302
KHR 4006.132888
KMF 422.149787
KPW 900.000346
KRW 1391.698708
KWD 0.305703
KYD 0.833695
KZT 543.546884
LAK 21640.332756
LBP 89638.254103
LKR 300.876974
LRD 200.581508
LSL 17.734525
LTL 2.95274
LVL 0.60489
LYD 5.424116
MAD 9.041825
MDL 16.77697
MGA 4414.133128
MKD 52.85829
MMK 2099.278286
MNT 3593.667467
MOP 8.089228
MRU 39.885935
MUR 45.380172
MVR 15.406089
MWK 1734.731128
MXN 18.62078
MYR 4.233503
MZN 63.959931
NAD 17.734068
NGN 1533.939706
NIO 36.813557
NOK 10.242685
NPR 140.288431
NZD 1.68624
OMR 0.38449
PAB 1.000417
PEN 3.52443
PGK 4.220011
PHP 57.042028
PKR 283.992682
PLN 3.659983
PYG 7493.26817
QAR 3.647944
RON 4.356598
RSD 100.784968
RUB 79.625717
RWF 1447.584853
SAR 3.752887
SBD 8.217066
SCR 14.742101
SDG 600.502857
SEK 9.620203
SGD 1.286405
SHP 0.785843
SLE 23.101353
SLL 20969.503947
SOS 571.715705
SRD 37.279016
STD 20697.981008
STN 21.043952
SVC 8.75335
SYP 13001.771596
SZL 17.738285
THB 32.426503
TJS 9.318983
TMT 3.51
TND 2.932287
TOP 2.342099
TRY 40.703802
TTD 6.789983
TWD 29.915994
TZS 2514.999777
UAH 41.483906
UGX 3564.541828
UYU 40.068886
UZS 12677.743946
VES 128.74775
VND 26233
VUV 119.401149
WST 2.653917
XAF 563.432871
XAG 0.026448
XAU 0.000298
XCD 2.70255
XCG 1.803033
XDR 0.700441
XOF 563.435291
XPF 102.435484
YER 240.450274
ZAR 17.767199
ZMK 9001.20435
ZMW 23.260308
ZWL 321.999592
- Stocks cautious before tariff updates, US data
- India look to break 'final barrier' in Women's World Cup
- Springboks move captain Kolisi to No 8 for Australia opener
- Mourners gather in Gaza for funeral of Al Jazeera staff killed by Israel
- Chinese vessels collide while pursuing Philippine boat in South China Sea
- EU to hold urgent Ukraine talks before Trump-Putin meeting
- Tributes to legendary Japan striker hailed by Pele
- Indian top court orders roundup of stray dogs in Delhi
- Stock markets mostly up at start of key week for trade, US data
- Indonesia, Peru strike trade agreement as leaders meet
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
A.Kwok--ThChM
